Biological therapeutic drug monitoring: a step towards precision medicine?
- PMID: 30262510
- DOI: 10.1136/archdischild-2018-315819
Biological therapeutic drug monitoring: a step towards precision medicine?
Keywords: bone disease; gastroenterology; musculoskeletal; pharmacology.
Conflict of interest statement
Competing interests: AVR is the co-chief investigator of the Sycamore study. AVR has received speaker fees/honoraria from Abbvie, SOBI, Lily, UCB and Roche.
Comment on
-
Drug monitoring in long-term treatment with adalimumab for juvenile idiopathic arthritis-associated uveitis.Arch Dis Child. 2019 Mar;104(3):246-250. doi: 10.1136/archdischild-2018-315060. Epub 2018 Jul 19. Arch Dis Child. 2019. PMID: 30026253
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical